$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
威罗非尼(佐博伏)应该如何用药?佐博伏的不良反应有哪些
2025-10-19 11:44:20
Check Details
比美替尼在哪里购买有保障?比美替尼的用法用量是怎样的?
2025-10-19 11:44:20
Check Details
比美替尼治疗效果好吗?比美替尼的副作用是什么?
2025-10-19 11:44:20
Check Details
强强联合:纳武单抗联合伊匹单抗(O+Y组合)大大延长晚期黑色素瘤患者生存期
2025-10-19 11:44:20
Check Details
BRAF V600突变的治疗方案—维莫非尼Zelboraf
2025-10-19 11:44:20
Check Details
全球黑色素瘤发病率高且呈上升趋势,我们应当如何预防?
2025-10-19 11:44:20
Check Details
达拉非尼治疗黑色素瘤的疗效和安全性怎么样?
2025-10-19 11:44:20
Check Details
恩考芬尼多少钱?辽宁可以购买到吗?
2025-10-19 11:44:20
Check Details
黑色素瘤治疗药物,曲美替尼深入解析
2025-10-19 11:44:20
Check Details
达卡巴嗪是化疗药还是靶向药?达卡巴嗪需要避光输注吗?
2025-10-19 11:44:20
Check Details
维莫非尼怎么吃好,一盒吃多长时间
2025-10-19 11:44:20
Check Details
维莫非尼吃几天开始有效果,吃完肿瘤能缩小吗
2025-10-19 11:44:20
Check Details
1
2
...
680
681
682
683
684
685
686
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
2
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
3
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
4
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
5
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
6
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
7
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
8
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
9
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
10
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
11
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
12
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma